摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

tert-butyl (1S)-2-[(6-bromoquinolin-3-yl)oxy]-1-(1H-indol-3-ylmethyl)ethylcarbamate | 552330-95-7

中文名称
——
中文别名
——
英文名称
tert-butyl (1S)-2-[(6-bromoquinolin-3-yl)oxy]-1-(1H-indol-3-ylmethyl)ethylcarbamate
英文别名
tert-butyl N-[(2S)-1-(6-bromoquinolin-3-yl)oxy-3-(1H-indol-3-yl)propan-2-yl]carbamate
tert-butyl (1S)-2-[(6-bromoquinolin-3-yl)oxy]-1-(1H-indol-3-ylmethyl)ethylcarbamate化学式
CAS
552330-95-7
化学式
C25H26BrN3O3
mdl
——
分子量
496.404
InChiKey
XINONXQMWREDHK-IBGZPJMESA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    5.7
  • 重原子数:
    32
  • 可旋转键数:
    8
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.28
  • 拓扑面积:
    76.2
  • 氢给体数:
    2
  • 氢受体数:
    4

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    tert-butyl (1S)-2-[(6-bromoquinolin-3-yl)oxy]-1-(1H-indol-3-ylmethyl)ethylcarbamate四(三苯基膦)钯三氟乙酸 作用下, 以 二氯甲烷N,N-二甲基甲酰胺 为溶剂, 反应 10.0h, 生成 (1S)-2-(1H-indol-3-yl)-1-[[(6-pyridin-4-ylquinolin-3-yl)oxy]methyl}ethylamine
    参考文献:
    名称:
    Synthesis and structure–activity relationship of 3,4′-bispyridinylethylenes: Discovery of a potent 3-isoquinolinylpyridine inhibitor of protein kinase B (PKB/Akt) for the treatment of cancer
    摘要:
    Structure-based design and synthesis of the 3,4'-bispyridinylethylene series led to the discovery of 3-isoquinolinylpyridine 13a as a potent PKB/Akt inhibitor with an IC50 of 1.3 nM against Akt1. Compound 13a shows excellent selectivity against distinct families of kinases such as tyrosine kinases and CAMK, and displays poor to marginal selectivity against closely related kinases in the AGC and CMGC families. Moreover, 13a demonstrates potent cellular activity comparable to staurosporine, with IC50 values of 0.42 and 0.59 mu M against MiaPaCa-2 and the Akt1 overexpressing FL5.12-Akt1, respectively. Inhibition of phosphorylation of the Akt downstream target GSK3 was also observed in FL5.12-Akt1 cells with an EC50 of 1.5 mu M. The X-ray structures of 12 and 13a in complex with PKA in the ATP-binding site were determined. (C) 2005 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2005.12.065
  • 作为产物:
    参考文献:
    名称:
    Synthesis and structure–activity relationship of 3,4′-bispyridinylethylenes: Discovery of a potent 3-isoquinolinylpyridine inhibitor of protein kinase B (PKB/Akt) for the treatment of cancer
    摘要:
    Structure-based design and synthesis of the 3,4'-bispyridinylethylene series led to the discovery of 3-isoquinolinylpyridine 13a as a potent PKB/Akt inhibitor with an IC50 of 1.3 nM against Akt1. Compound 13a shows excellent selectivity against distinct families of kinases such as tyrosine kinases and CAMK, and displays poor to marginal selectivity against closely related kinases in the AGC and CMGC families. Moreover, 13a demonstrates potent cellular activity comparable to staurosporine, with IC50 values of 0.42 and 0.59 mu M against MiaPaCa-2 and the Akt1 overexpressing FL5.12-Akt1, respectively. Inhibition of phosphorylation of the Akt downstream target GSK3 was also observed in FL5.12-Akt1 cells with an EC50 of 1.5 mu M. The X-ray structures of 12 and 13a in complex with PKA in the ATP-binding site were determined. (C) 2005 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2005.12.065
点击查看最新优质反应信息

文献信息

  • Kinase inhibitors
    申请人:——
    公开号:US20030199511A1
    公开(公告)日:2003-10-23
    Compounds having the formula 1 are useful for inhibiting protein kinases. Also disclosed are compositions which inhibit protein kinases and methods of inhibiting protein kinases in a patient.
    具有以下化学式的化合物对抑制蛋白激酶很有用。还公开了抑制蛋白激酶的组合物以及在患者中抑制蛋白激酶的方法。
  • Synthesis and structure–activity relationship of 3,4′-bispyridinylethylenes: Discovery of a potent 3-isoquinolinylpyridine inhibitor of protein kinase B (PKB/Akt) for the treatment of cancer
    作者:Qun Li、Keith W. Woods、Sheela Thomas、Gui-Dong Zhu、Garrick Packard、John Fisher、Tongmei Li、Jianchun Gong、Jurgen Dinges、Xiaohong Song、Jason Abrams、Yan Luo、Eric F. Johnson、Yan Shi、Xuesong Liu、Vered Klinghofer、Ron Des Jong、Tilman Oltersdorf、Vincent S. Stoll、Clarissa G. Jakob、Saul H. Rosenberg、Vincent L. Giranda
    DOI:10.1016/j.bmcl.2005.12.065
    日期:2006.4
    Structure-based design and synthesis of the 3,4'-bispyridinylethylene series led to the discovery of 3-isoquinolinylpyridine 13a as a potent PKB/Akt inhibitor with an IC50 of 1.3 nM against Akt1. Compound 13a shows excellent selectivity against distinct families of kinases such as tyrosine kinases and CAMK, and displays poor to marginal selectivity against closely related kinases in the AGC and CMGC families. Moreover, 13a demonstrates potent cellular activity comparable to staurosporine, with IC50 values of 0.42 and 0.59 mu M against MiaPaCa-2 and the Akt1 overexpressing FL5.12-Akt1, respectively. Inhibition of phosphorylation of the Akt downstream target GSK3 was also observed in FL5.12-Akt1 cells with an EC50 of 1.5 mu M. The X-ray structures of 12 and 13a in complex with PKA in the ATP-binding site were determined. (C) 2005 Elsevier Ltd. All rights reserved.
查看更多